Genetically engineered nanovesicles based anti-EphA2/CD3 bispecific antibody promotes T cell immune response for triple negative breast cancer treatment(KTB1410-13.2)
Genetically engineered nanovesicles based anti-EphA2/CD3 bispecific antibody promotes T cell immune response for triple negative breast cancer treatment(KTB1410-13.2)